Hydrogel-based colorectal cancer organoid co-culture models

Luo, Xin; Fong, Eliza Li Shan; Zhu, Ce; Lin, Quy Xiao Xuan; Xiong, Man; Li, Aimin; Li, Tingting; Benoukraf, Touati; Yu, Hanry; Liu, Side

doi:10.1016/j.actbio.2020.12.037

Cited by 103 publications

(86 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Leading the front on CAF heterogeneity, the Tuveson group recently demonstrated the existence of two CAF subpopulations using co-culture models comprising pancreatic cancer organoids with pancreatic stellate cells in Matrigel ® . Of notable mention, as reported in this study (and our own study 323 ), the integration of CAFs into organoid-based models requires significant optimization, as several factors present in organoid media, including Noggin, B27 and TGF-β inhibitor, can significantly inhibit fibroblast growth. 324 Leveraging this developed co-culture model, the authors showed that two distinct CAF subpopulations exist, including a myofibroblastictype adjacent to the cancer organoids, and a more inflammatory-type further away.…”

Section: Biomaterials Science Reviewmentioning

confidence: 58%

Hydrogels to engineer tumor microenvironmentsin vitro

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Biomaterials Science Reviewmentioning

confidence: 58%

Hydrogels to engineer tumor microenvironmentsin vitro

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…This study also shows a great opportunity to replace the dysfunctional bladders and test the anticancer drug for the patients. Moreover, many bioengineering approaches are explored for tumor organoid cultures, including ECM scaffolds (i.e., Matrigels, hydrogels, and collagens), [ 176–178 ] spinning bioreactor, [ 176,179 ] low‐adherent culture plate, [ 180 ] 3D bioprinting, [ 176,181,182 ] hanging‐drop, [ 183 ] micropatterning [ 128,184 ] and microfluidic. [ 185,186 ] Drug screening and tumor organoid banking have recently been developed for personalized anticancer drugs and new drug testing.…”

Section: Expansion Of Rare Cancer Cellsmentioning

confidence: 99%

Expansion of Rare Cancer Cells into Tumoroids for Therapeutic Regimen and Cancer Therapy

Enkhbat

Liu

Kim

et al. 2021

Advanced Therapeutics

View full text Add to dashboard Cite

Rare cancer cells, such as circulating tumor cells (CTCs) and cancer stem cells (CSCs), are small cell population found in cancer patients. CTCs have been recognized as tumor avatars for real-time cancer monitoring, while CSCs are the most malignant tumor cells that play a dominant role in drug resistance and metastasis. Interestingly, these two types of cells share the same surface markers, such as EpCAM, CD44, and CD133. While capturing these rare cells is available, the expansion of these cells is still challenging due to the limited cell number. These cells are susceptible to the microenvironment and lose the capability to grow in vitro, especially after an intense capturing process. A technology called patient-derived tumor organoids (PDOs) or tumoroids is a rising start in cancer modeling but the applicability is still questionable. Recently, assembloids containing multiple tumor-related cells have been developed which is one step closer to the real tumor. In this review, strategies for in vitro expansion of tumoroids are summarized implying that artificial tumor niche composed of optimized biophysical and biological cues is vital in the tumoroid generation. Tumoroids containing rare cancer cells is believed to be beneficial in the diagnosis, therapeutic regimen, and drug discovery for personalized therapy.

show abstract

“…To further recapitulate the in vivo physiology of the tumour and surrounding stroma and cell constituents, efforts have turned to incorporation of other important cell types to create co-culture organoids, with significant strides made in other cancer types developing co-cultures with immune cells [104] and/or cancer associated fibroblasts [105][106][107][108]. Limited work to date has been done on co-cultures of genital tract tissue or cancer PDOs as part of broader efforts to establish 3D cultures to include the wider immune microenvironment.…”

Section: Clinical Perspectivementioning

confidence: 99%

Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies

Cunnea

Fotopoulou

Ploski

et al. 2021

Cancers

View full text Add to dashboard Cite

Gynaecological malignancies represent a heterogeneous group of neoplasms with vastly different aetiology, risk factors, molecular drivers, and disease outcomes. From HPV-driven cervical cancer where early screening and molecular diagnostics efficiently reduced the number of advanced-stage diagnosis, prevalent and relatively well-treated endometrial cancers, to highly aggressive and mostly lethal high-grade serous ovarian cancer, malignancies of the female genital tract have unique presentations and distinct cell biology features. Recent discoveries of stem cell regulatory mechanisms, development of organoid cultures, and NGS analysis have provided valuable insights into the basic biology of these cancers that could help advance new-targeted therapeutic approaches. This review revisits new findings on stemness and differentiation, considering main challenges and open questions. We focus on the role of stem cell niche and tumour microenvironment in early and metastatic stages of the disease progression and highlight the potential of patient-derived organoid models to study key events in tumour evolution, the appearance of resistance mechanisms, and as screening tools to enable personalisation of drug treatments.

show abstract

Hydrogel-based colorectal cancer organoid co-culture models

Cited by 103 publications

References 52 publications

Hydrogels to engineer tumor microenvironmentsin vitro

Hydrogels to engineer tumor microenvironmentsin vitro

Expansion of Rare Cancer Cells into Tumoroids for Therapeutic Regimen and Cancer Therapy

Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies

Contact Info

Product

Resources

About